logo
  

Immunome Expects Its Three-antibody Cocktail IMM-BCP-01 To Neutralize Omicron Variant; Stock Up 18%

Biopharmaceutical company Immunome, Inc. (IMNM) announced Wednesday that it has conducted an assessment of the reported mutations in the new SARS-CoV-2 variant, Omicron (B.1.1.529).

Based upon structural mapping of those mutations and activity against previous and current CDC variants of concern, Immunome expects its three-antibody cocktail, IMM-BCP-01, to neutralize the Omicron variant.

The Omicron variant has a number of mutations across the ACE2 receptor binding site. IMM-BCP-01 is an antibody cocktail designed to target three distinct, non-overlapping epitopes. Two of IMM-BCP-01's three antibodies target epitopes outside of the ACE2 receptor binding site.

The Company is diligently working to confirm this activity in laboratory testing and expects initial results to be available in January 2022.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Covid vaccine makers Pfizer Inc. and BioNTech SE announced a new $3.2 billion vaccine supply deal with the U.S. Government, as the country is bracing for a Covid outbreak this fall. Under the deal, the U.S. government will receive 105 million doses (30 µg, 10 µg and 3 µg) of Pfizer -BioNTech covid vaccines initially. The order may include adult Omicron-adapted COVID-19 vaccines. Samsung Electronics Co. has started the initial mass production of 3-nanometer or nm chips, which is considered as the most advanced chip in the world. In its move, the South Korean tech major beats rival Taiwan Semiconductor Manufacturing Co., the world's largest chip manufacturer, which is reportedly in the process to build one. Bryant Ranch Prepack Inc. is recalling certain Morphine Sulfate Extended-Release Tablets citing incorrect labeling, the U.S. Food and Drug Administration said. The recall involves one lot of Morphine Sulfate 30 mg Extended-Release tablets, and one lot of Morphine Sulfate 60 mg Extended-Release tablets to the consumer level.
Follow RTT